Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VapoCool Adds Menthol To P&G's DayQuil, NyQuil Cough/Cold Remedies

Executive Summary

Liquid and caplet DayQuil and NyQuil Severe with VapoCool, also offered in cold/flu formulations, are on retailer shelves ready for the cold season. P&G also increases amount of menthol in its Vicks Severe Medicated Drops sore throat lozenges to mark 125th anniversary Vicks line introduction.

You may also be interested in...



P&G Stretches ZzzQuil Sleep Brand Into Supplement Space With PureZzzs

P&G will launch Vicks ZzzQuil PureZzzs in late February as a drug-free, melatonin-based sleep aid, CFO Jon Moeller says. P&G hopes to reach $4.5bn in e-commerce sales in 2018, up from $3bn in 2017.

Qualifying Suppliers For US Supplement Ingredient Identity Requirement Still An Option With Thorns

Failing to qualify suppliers “one of the more common citations” FDA inspectors find at supplement facilities, says ORA deputy director Michael Dutcher. “If you're not sort of reconfirming once in a while it could lead to a problem with your products that you weren't even expecting.”

US OTC Switch For Cialis At Top Of To-Do List For Sanofi’s North American Consumer Health Chief

Andrew Loucks moves to Sanofi from helm of consumer health and technology firm Sensory Cloud as business navigates gaining US OTC heartburn market share for Zantac brand, which it relaunched with famotidine replacing ranitidine as the active ingredient.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel